Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) and Cellectis S.A. (NASDAQ:CLLS) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Demonstrates Aerpio Pharmaceuticals Inc. and Cellectis S.A. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 provides Aerpio Pharmaceuticals Inc. and Cellectis S.A.’s net margins, return on equity and return on assets.

Liquidity

Aerpio Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 13.8 and 13.8 respectively. The Current Ratio and Quick Ratio of its competitor Cellectis S.A. are 9.8 and 9.7 respectively. Aerpio Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Cellectis S.A.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Aerpio Pharmaceuticals Inc. and Cellectis S.A.

Competitively Cellectis S.A. has an average target price of $38.67, with potential upside of 214.13%.

Insider & Institutional Ownership

Aerpio Pharmaceuticals Inc. and Cellectis S.A. has shares held by institutional investors as follows: 23.4% and 31.4%. Insiders held roughly 1.1% of Aerpio Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Aerpio Pharmaceuticals Inc.’s stock price has bigger decline than Cellectis S.A.

Summary

On 6 of the 8 factors Cellectis S.A. beats Aerpio Pharmaceuticals Inc.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.